Equities

BrightPath Biotherapeutics Co Ltd

4594:TYO

BrightPath Biotherapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)56.00
  • Today's Change2.00 / 3.70%
  • Shares traded2.13m
  • 1 Year change-43.43%
  • Beta1.2250
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,0571,5312,305
Total Receivables, Net0.010.0617
Total Inventory------
Prepaid expenses------
Other current assets, total124120374
Total current assets1,1811,6512,696
Property, plant & equipment, net0025
Goodwill, net------
Intangibles, net000
Long term investments------
Note receivable - long term------
Other long term assets495050
Total assets1,2301,7012,771
LIABILITIES
Accounts payable0.020.081.91
Accrued expenses6.094.055.44
Notes payable/short-term debt000
Current portion long-term debt/capital leases113088
Other current liabilities, total727290
Total current liabilities19177185
Total long term debt000
Total debt113088
Deferred income tax000
Minority interest------
Other liabilities, total605755
Total liabilities251134240
SHAREHOLDERS EQUITY
Common stock6513626,700
Additional paid-in capital2,9592,6716,684
Retained earnings (accumulated deficit)(2631)(1465)(10853)
Treasury stock - common00--
Unrealized gain (loss)------
Other equity, total0.000.000.00
Total equity9791,5682,531
Total liabilities & shareholders' equity1,2301,7012,771
Total common shares outstanding716355
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.